This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Momenta Pharmaceuticals, Inc. ( MNTA)

Q3 2011 Earnings Call

November 07, 2011 10:00 am ET


Beverly Holley - Director, IR

Craig Wheeler - President & CEO

Rick Shea - CFO


Ritu Baral - Canaccord

Eric Schmidt - Cowen and Company

Sapna Srivastava - Goldman Sachs

Joseph Schwartz - Leerink

Bret Holley - Oppenheimer Securities

Duane Nash - Wedbush Securities

Ami Fadia - UBS

Avik Roy - Monness, Crespi



Good day, ladies and gentlemen, and welcome to the Momenta Pharmaceuticals third quarter 2011 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to introduce your host for today, Ms. Beverly Holley, Director of Investor Relations. Ma’am, please go ahead.

Beverly Holley

Thank you and good morning. I want to welcome all of you to Momenta’s conference call to discuss financial results for the third quarter of 2011 and to provide a corporate update. With me on the call today with prepared remarks, Mr. Craig Wheeler, President and Chief Executive Officer, and Rick Shea, Chief Financial Officer. Following our remarks, we’ll open the call to questions.

Before we begin, I’d like to mention that our call today will contain forward-looking statements about management’s future expectations, beliefs, plans and prospects. These forward-looking statement including comments about our enoxaparin sodium injection commercial prospects and our generic competitors’ prospects for approval and commercialization; our generic Copaxone program, ANDA review and litigation expectations; and our other product development plans and expectations, including our future development, partnering and commercialization potential for our development programs.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.71 -0.33%
FB $98.23 -5.60%
GOOG $667.78 -2.30%
TSLA $147.86 -9.10%
YHOO $26.91 -3.80%


Chart of I:DJI
DOW 15,856.11 -348.86 -2.15%
S&P 500 1,831.75 -48.30 -2.57%
NASDAQ 4,219.1690 -143.9750 -3.30%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs